Core Viewpoint - The announcement highlights the upcoming launch of the Iberis® RDN system, a renal denervation product developed by Shanghai Antong Medical Technology Co., Ltd., scheduled for presentation at the OCC2025 conference on May 31, 2025 [1][2] Group 1: Product Launch and Event Details - The Iberis® RDN system is set to be introduced at the 19th Oriental Cardiology Conference (OCC2025) [1] - The launch event will feature prominent medical professionals as chairs and speakers, including professors from Fudan University, Zhejiang University, and Basel University [1] - The event will be hosted by Professor Liu Jian from Peking University People's Hospital [1] Group 2: Product Features and Market Strategy - The Iberis® RDN system is the only globally approved renal denervation product compatible with both transradial access (TRA) and femoral access [2] - TRA enhances the safety, efficacy, and cost-effectiveness of renal denervation procedures [2] - The product will be jointly promoted in China by Antong Medical and Kainow Medical Technology (Wuhan) Co., Ltd., a subsidiary of United Pharmaceutical Group [2]